High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA

Clinical and Vaccine Immunology

Volumn 15, Issue 9, 2008, Pages 1337-1344

  Melhem, Nada M ^a   Gleason, Sherrianne M ^a   Liu, Xiang Dong ^a   Barratt Boyes, Simon M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; HLA DR ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA; WILD TYPE VIRAL MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DNA TRANSFECTION; EFFECTOR CELL; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; IN VIVO STUDY; INTERMETHOD COMPARISON; LIPOFECTION; MONKEY; MRNA NUCLEOFECTION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REACTION OPTIMIZATION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS GENE; WILD TYPE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; DENDRITIC CELLS; GENE PRODUCTS, GAG; HUMANS; MACACA MULATTA; RNA, MESSENGER; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 51649115332     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00154-08     Document Type: Article

References (51)

1. Afonina, E., M. Neumann, and G. N. Pavlakis. 1997. Preferential binding of poly (A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA. J. Biol. Chem. 272:2307-2311.
2. Artusio, E., B. Hathaway, J. Stanson, and T. L. Whiteside. 2006. Transfection of human monocyte-derived dendritic cells with native tumor DNA induces antigen-specific T-cell responses in vitro. Cancer Biol. Ther. 5:1624-1631.
3. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
4. Barratt-Boyes, S. M., A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, and A. Gambotto. 2006. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J. Gen. Virol. 87:139-149.
5. Barratt-Boyes, S. M., S. C. Watkins, and O. J. Finn. 1997. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J. Immunol. 158:4543-4547.
6. Barratt-Boyes, S. M., M. I. Zimmer, L. A. Harshyne, E. M. Meyer, S. C. Watkins, S. Capuano III, M. Murphey-Corb, L. D. Falo, Jr., and A. D. Donnenberg. 2000. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J. Immunol. 164:2487-2495.
7. Baum, C., P. Forster, S. Hegewisch-Becker, and K. Harbers. 1994. An optimized electroporation protocol applicable to a wide range of cell lines. BioTechniques 17:1058-1062.
8. Berg, O. G., and C. G. Kurland. 1997. Growth rate-optimised tRNA abundance and codon usage. J. Mol. Biol. 270:544-550.
9. Curti, A., S. Pandolfi, M. Aluigi, A. Isidori, I. Alessandrini, C. Chiodoni, N. Testoni, M. P. Colombo, M. Baccarani, and R. M. Lemoli. 2005. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp. Hematol. 33:1521-1530.
10. Dannull, J., S. Nair, Z. Su, D. Boczkowski, C. DeBeck, B. Yang, E. Gilboa, and J. Vieweg. 2005. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105:3206-3213.
11. Dullaers, M., K. Breckpot, S. Van Meirvenne, A. Bonehill, S. Tuyaerts, A. Michiels, L. Straetman, C. Heirman, C. De Greef, P. Van Der Bruggen, and K. Thielemans. 2004. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. 10:768-779.
12. Engelmayer, J., M. Larsson, M. Subklewe, A. Chahroudi, W. I. Cox, R. M. Steinman, and N. Bhardwaj. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163:6762-6768.
13. Eppler, E., H. Horig, H. L. Kaufman, P. Groscurth, and L. Filgueira. 2002. Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA. Eur. J. Cancer 38:184-193.
14. Gao, W., A. Rzewski, H. Sun, P. D. Robbins, and A. Gambotto. 2004. UpGene: application of a web-based DNA codon optimization algorithm. Biotechnol. Prog. 20:443-448.
15. Gärtner, A., L. Collin, and G. Lalli. 2006. Nucleofection of primary neurons. Methods Enzymol. 406:374-388.
16. Gilboa, E. 2007. DC-based cancer vaccines. J. Clin. Investig. 117:1195-1203.
17. Gresch, O., F. B. Engel, D. Nesic, T. T. Tran, H. M. England, E. S. Hickman, I. Korner, L. Gan, S. Chen, S. Castro-Obregon, R. Hammermann, J. Wolf, H. Muller-Hartmann, M. Nix, G. Siebenkotten, G. Kraus, and K. Lun. 2004. New non-viral method for gene transfer into primary cells. Methods 33:151-163.
18. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M. A. Maurice, C. D. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Investig. 109:409-417.
19. Heiser, A., M. A. Maurice, D. R. Yancey, N. Z. Wu, P. Dahm, S. K. Pruitt, D. Boczkowski, S. K. Nair, M. S. Ballo, E. Gilboa, and J. Vieweg. 2001. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166:2953-2960.
20. Hou, W. S., and L. Van Parijs. 2004. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5:583-589.
21. Jacobsen, F., J. Mertens-Rill, J. Seller, T. Hirsch, A. Daigeler, S. Langer, M. Lehnhardt, H. U. Steinau, and L. Steinstraesser. 2006. Nucleofection: a new method for cutaneous gene transfer? J. Biomed. Biotechnol. 2006:26060.
22. Javorovic, M., H. Pohla, B. Frankenberger, T. Wolfel, and D. J. Schendel. 2005. RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol. Ther. 12:734-743.
23. Jenne, L., G. Schuler, and A. Steinkasserer. 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22:102-107.
24. Kaliński, P., C. M. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20:561-567.
25. + T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 107:1963-1969.
26. Kypr, J., and J. Mrázek. 1987. Unusual codon usage of HIV. Nature 327:20.
27. Landi, A., L. A. Babiuk, and S. van Drunen Littel-van den Hurk. 2007. High transfection efficiency, gene expression, and viability of monocyte-de rived human dendritic cells after nonviral gene transfer. J. Leukoc. Biol. 82:849-860.
28. Larregina, A. T., A. E. Morelli, O. Tkacheva, G. Erdos, C. Donahue, S. C. Watkins, A. W. Thomson, and L. D. Falo, Jr. 2004. Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood 103:811-819.
29. Lenz, P., S. M. Bacot, M. R. Frazier-Jessen, and G. M. Feldman. 2003. Nucleoporation of dendritic cells: efficient gene transfer by electroporation into human monocyte-derived dendritic cells. FEBS Lett. 538:149-154.
30. Li, X., X. Zhao, Y. Fang, X. Jiang, T. Duong, C. Fan, C. C. Huang, and S. R. Kain. 1998. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273:34970-34975.
31. Liao, X., Y. Li, C. Bonini, S. Nair, E. Gilboa, P. D. Greenberg, and C. Yee. 2004. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol. Ther. 9:757-764.
32. Lu, W., L. C. Arraes, W. T. Ferreira, and J.-M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
33. + T-cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. Eur. J. Immunol. 37:2164-2173.
34. Michiels, A., S. Tuyaerts, A. Bonehill, J. Corthals, K. Breckpot, C. Heirman, S. Van Meirvenne, M. Dullaers, S. Allard, F. Brasseur, P. van der Bruggen, and K. Thielemans. 2005. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 12:772-782.
35. Morelli, A. E., A. T. Larregina, R. W. Ganster, A. F. Zahorchak, J. M. Plowey, T. Takayama, A. J. Logar, P. D. Robbins, L. D. Falo, and A. W. Thomson. 2000. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J. Virol. 74:9617-9628.
36. Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59:56-58.
37. Nagaraj, S., C. Ziske, and I. G. Schmidt-Wolf. 2004. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet. Vaccines Ther. 2:12.
38. Nestle, F. O., A. Farkas, and C. Conrad. 2005. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17:163-169.
39. Ponsaerts, P., V. F. I. Van Tendeloo, and Z. N. Berneman. 2003. Cancer immunotherapy using RNA-loaded dendritic cells. Clin. Exp. Immunol. 134:378-384.
40. Saebøe-Larssen, S., E. Fossberg, and G. Gaudernack. 2002. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J. Immunol. Methods 259:191-203.
41. Strobel, I., S. Berchtold, A. Gotze, U. Schulze, G. Schuler, and A. Steinkasserer. 2000. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7:2028-2035.
42. Su, Z., J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2127-2133.
43. + T-cell responses in patients with metastatic prostate cancer. J. Immun. 174:3798-3807.
44. Thomas, R., M. Chambers, R. Boytar, K. Barker, L. L. Cavanagh, S. Mac-Fadyen, M. Smithers, M. Jenkins, and J. Andersen. 1999. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 9:474-481.
45. Tüting, T., C. C. Wilson, D. M. Martin, J. Baar, A. DeLeo, M. T. Lotze, and W. J. Storkus. 1998. DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv. Exp. Med. Biol. 451:295-304.
46. Tuyaerts, S., A. Michiels, J. Corthals, A. Bonehill, C. Heirman, C. de Greef, S. M. Noppe, and K. Thielemans. 2003. Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 10:696-706.
47. Van De Parre, T. J., W. Martinet, D. M. Schrijvers, A. G. Herman, and G. R. De Meyer. 2005. mRNA but not plasmid DNA is efficiently transfected in murine J774A.1 macrophages. Biochem. Biophys. Res. Commun. 327:356-360.
48. Van Gulck, E. R., P. Ponsaerts, L. Heyndrickx, K. Vereecken, F. Moerman, A. De Roo, R. Colebunders, G. Van den Bosch, D. R. Van Bockstaele, V. F. Van Tendeloo, S. Allard, B. Verrier, C. Maranon, G. Hoeffel, A. Hosmalin, Z. N. Berneman, and G. Vanham. 2006. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 107:1818-1827.
49. van Leeuwen, E. B., S. Cloosen, B. L. Senden-Gijsbers, W. T. Germeraad, and G. M. Bos. 2006. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy 8:36-46.
50. Van Tendeloo, V. F., P. Ponsaerts, F. Lardon, G. Nijs, M. Lenjou, C. Van Broeckhoven, D. R. Van Bockstaele, and Z. N. Berneman. 2001. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49-56.
51. Van Tendeloo, V. F., H. W. Snoeck, F. Lardon, G. L. Vanham, G. Nijs, M. Lenjou, L. Hendriks, C. Van Broeckhoven, A. Moulijn, I. Rodrigus, P. Verdonk, D. R. Van Bockstaele, and Z. N. Berneman. 1998. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther. 5:700-707.